Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China-Developed Artificial Skin Ready For Production

This article was originally published in PharmAsia News

Executive Summary

Shaanxi Province has broken ground for its Research and Development Center for Tissue Engineering in Xi'an High-Tech Industrial Development Zone. With a total investment of RMB 120 million, the project is expected to realize a yearly revenue of RMB 1 billion when it goes into operation. The facility will have an annual output of 3 million cm2 of artificial skin, 30,000 corneas and 10 million cm2 of selective acellular double-layer dermal matrix produced by tissue engineering. Developed by Fourth Military Medical University, it is the nation's only such technology with independent intellectual property rights that can successfully produce engineered tissue products. The project makes China the second country to commercialize tissue engineering technology after the U.S. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel